April 2014
Volume 55, Issue 13
ARVO Annual Meeting Abstract  |   April 2014
Vascular endothelial growth factor (VEGF)-induced retinal vascular leakage in African green monkeys
Author Affiliations & Notes
  • Wenzheng Hu
    RxGen Inc, Hamden, CT
  • Vernard Woodley
    RxGen Inc, Hamden, CT
  • Rohn Brookes
    RxGen Inc, Hamden, CT
  • Mike Struharik
    RxGen Inc, Hamden, CT
  • Steve Whittaker
    RxGen Inc, Hamden, CT
  • Steve Henry
    RxGen Inc, Hamden, CT
  • Robin J Goody
    RxGen Inc, Hamden, CT
  • Matthew S Lawrence
    RxGen Inc, Hamden, CT
  • Footnotes
    Commercial Relationships Wenzheng Hu, RxGen Inc. (E); Vernard Woodley, RxGen Inc. (E); Rohn Brookes, RxGen Inc. (E); Mike Struharik, RxGen Inc. (E); Steve Whittaker, RxGen Inc. (E); Steve Henry, RxGen Inc. (E); Robin Goody, RxGen Inc. (E); Matthew Lawrence, RxGen Inc. (E)
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science April 2014, Vol.55, 2245. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Wenzheng Hu, Vernard Woodley, Rohn Brookes, Mike Struharik, Steve Whittaker, Steve Henry, Robin J Goody, Matthew S Lawrence; Vascular endothelial growth factor (VEGF)-induced retinal vascular leakage in African green monkeys. Invest. Ophthalmol. Vis. Sci. 2014;55(13):2245.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose: To characterize the time course of pathologic features such as retinal vascular leakage following intravitreal (IVT) injection of recombinant human VEGF165 (rhVEGF) in African green monkeys (AGMs), and to evaluate the effect of anti-VEGF therapy in reducing the pathogenic changes elicited in this model.

Methods: Eight adult male and female AGMs received repeat bilateral IVT injections of 1 or 2 µg of rhVEGF. Eyes were examined by color fundus photography, fluorescence angiography and optical coherence tomography. Lucentis 0.25 mg was administered intravitreally 2 days after the second dose of rhVEGF.

Results: A minimum of two serial IVT rhVEGF injections were necessary to induce significant retinal vascular leakage in AGMs. Following initial dosing with 2 µg rhVEGF, the retinal appearance was similar to that observed in eyes receiving a first dose of 1 µg rhVEGF. Slight vascular dilation occurred in all eyes at day 2 with a minor retinal hemorrhage, and resolved by day 3. Two days after a second 2 µg IVT dose of rhVEGF, there was moderate dilation and tortuosity of retinal vessels, and minor vascular sheathing in the posterior retina. Changes peaked at day 3 with small patches of intra-retinal hemorrhage occurring in the posterior region. Six days after the second rhVEGF dose, moderate dilation and tortuosity of retinal vessels, and multiple intra-retinal hemorrhages were seen in both the posterior and nasal retina. Vascular dilation and tortuosity fully resolved within 11 days of the second dose. Intra-retinal hemorrhages also resolved but abundant hard exudates were deposited in the posterior retina. Lucentis-treated eyes demonstrated no fluorescein leakage in the retina although the fluorescein signal was still evident in the optic nerve head 1 day post-Lucentis treatment. No retinal vascular pathology was observed 4 days post-Lucentis injection and thereafter.

Conclusions: Intravitreal injections of rhVEGF produced retinal vascular leakage and other pathological changes including vascular dilation, tortuosity and sheathing, intra-retinal hemorrhage, exudates and non-perfusion regions. Pathological features were similar to those seen in diabetic retinopathy. Lucentis effectively inhibited rhVEGF-induced vascular leakage and other pathological changes, thus supporting its use as a positive control for testing anti-vascular leakage compounds in the rhVEGF model.

Keywords: 688 retina • 499 diabetic retinopathy • 748 vascular endothelial growth factor  

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.